pharmaceutical industry
Is it a good time to be a data scientist in the pharmaceutical industry?
June 04 by Pharma IQWe discuss how the role of data analytics is changing in the industry and what the real "value add" is
Pharma Industry Commuter Digest: Sept 2018
September 03 by Pharma IQ NewsPharma IQ's Industry Commuter Digest packages all you need to know about the month's pharmaceutical market activity on one convenient page.
How to Engage With 100,000 Senior Pharma Professionals. Find Out 5 Techniques to Capture Industry Attention
June 22 by Pharmaceuticals & Biotechnology EditorIn this whitepaper you will find out what it takes to successfully engage with pharma professionals. Pharma IQ has grown year on year by meeting the demand for high quality resources for busy prof...
Shifting Patterns in the Pharmaceutical Industry
July 06 by Pharmaceuticals & Biotechnology EditorThis favourable combination of supply and demand factors served the industry well. The global research-based pharmaceutical industry –comprising those firms focused primarily on the research,...
Pharmaceuticals Companies Need Radical Transformation to be the Winners in 2020, According to KPMG’s Future Pharma Research
October 20 by Pharma IQ NewsGlobal pharmaceutical companies need to undergo a radical transformation of their investment and business strategies in order to reverse a prolonged period of disappointing business performance and...
Future Pharma: Five Strategies to Accelerate the Transformation of the Pharmaceutical Industry by 2020
October 20 by Pharmaceuticals & Biotechnology EditorThis paper explores some of the major challenges facing the pharmaceutical industry today. Four Major Challenges Facing the Pharmaceutical Industry: 1. Delivering shareholder/stakeholder value...
Exclusive: Dr. Yves Juillet, DIA President Speaks to Pharma IQ about the Top 3 Regulations Impacting Pharma in 2011 -2012
July 21 by Pharmaceuticals & Biotechnology EditorIn this video Dr. Yves Juillet, DIA President, speaks to Andrea Charles from Pharma IQ, about the top 3 regulations impacting pharma in 2011 -2012 at DIA's 47th Annual Meeting. Juillet...
30 Years On - Developing Cost–Effective Drug Discovery Programs Remains the No.1 Challenge
April 25 by Pharma IQDr. Andrew Alexander Parsons, Director at Reciprocal Minds Limited and former VP Preclinical Drug Development and External Discovery at GSK, discusses current and future burning issues in the&...
Assessing the Impact of Globalisation on Pharmaceutical Counterfeiting
April 25 by Jeffrey GrenJeffrey Gren, Director of the Office of Health and Consumer Goods, joins Pharma IQ to address some solutions to the increase in the volume and the level of sophistication of counterfeiting as part of...
DIA's Yves Juillet Speaks to Pharma IQ about the Road to Convergence
April 25 by Dr. Yves JuilletDr. Yves Juillet, DIA President, speaks to Pharma IQ, about the top 3 regulations impacting pharma in 2011 -2012 at DIA's 47th Annual Meeting. Juillet discusses the DIA's top priorities...